Vice President, Biochemistry and Biophysics

Anil Padyana is an accomplished and innovative drug discovery leader with over 20 years of experience in the biotech and pharmaceutical industry. He is an expert drug hunter with broad expertise in molecular targets, lead discovery, mechanistic biochemistry, biophysics, and structure-based drug design (SBDD). He was previously the Director of Structural Biology and Biophysics at Agios Pharmaceuticals, where he built next-gen fragment-based drug discovery efforts resulting in the discovery of molecules to address unmet needs in precision oncology and genetically defined diseases. Prior to Agios, he was the Crystallography Team and Project Leader at Boehringer Ingelheim Pharmaceuticals, where he contributed to successful NCE and NBE drug discovery spanning cardio-metabolic, chronic kidney diseases, virology, immunology, and inflammation therapeutic areas. He started his career in biotech at SGX Pharmaceuticals in San Diego. Anil has made major contributions to the discovery and development of FDA-approved precision medicines (IDHIFA®, SPEVIGO®) and over 10 clinical stage, investigational new drugs. He is an author and co-inventor on more than 35 publications and patents.

Anil received his PhD in Biophysics and Bioinformatics from the Indian Institute of Science (IISc), India. He was a postdoctoral fellow in the laboratory of Prof. Stephen Burley at Rockefeller University in New York.